RoActemra (tocilizumab): Temporary supply shortage for 162 mg solution for subcutaneous injection and RoActemra 20 mg/mL concentrate for solution for infusion (IV) & recommendations to manage potential risk of disease flare in patient
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
RoActemra
|
| Active substance |
tocilizumab
|
| Therapeutic area (MeSH) |
|
| DHPC type |
Medicine shortage
|
| Human ATC code |
L04AC07
|
| Dissemination date |
03/09/2020
|